News
As of January 2020, Dr. Baum will be located at the THERANOSTICS CENTER FOR RADIOMOLECULAR PRECISION ONCOLOGY in Wiesbaden (very close to Frankfurt/Main airport (20 minutes by car or commuter train)). Dr. Baum will have full access to complete diagnostic and treatment facilities.
As of December 15, 2019, please use the following contact information:
Professor Dr. Richard P. Baum, MD, PhD
THERANOSTICUM Frankfurt-Wiesbaden
at DKD Clinic
Aukammallee 33
65191 Wiesbaden, Germany
https://www.praxis-nuklearmedizin.de/en/
To send an email This email address is being protected from spambots. You need JavaScript enabled to view it.
Dr. Harshad R. Kulkarni, MD, will manage the care of those patients who will still need to be treated at ZBB due to special technical requirements (e.g. ALPHA-PRRT, intra-arterial PRRT
1/26/18 - Advanced Accelerator Applications (AAA) Receives FDA Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine
AAA announced that the Federal Drug Administration (FDA) has approved the new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Click here to read the company press release or here to read the full prescribing information.
US Locations offering Lutathera
NorCal CarciNET President, Josh Mailman discusses this with Drs. Hope, Kunz, Strossberg, and Liu on Facebook. Click here
Advanced Accelerator Applications (AAA) Receives European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine
AAA announced on September 29, 2017 that the European Commission (EC) has approved the marketing authorization of lutetium (177Lu) oxodotreotide* (Lutathera®) for “the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Videos from Patient Education Day on NETs from the SNMMI Annual Meeting
Philidelphia, June 2018
Introduction to Theranostic from Zentralklink Bad Berka
AAA Opens Lutathera Expanded Access Program In U.S. to Eligible Patients And Announces Forthcoming NDA Filing to FDA and EMA.
AAA today announced that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program, Lutathera is being made available for patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy. Healthcare
The results from the first randomized control trial of PRRT were released today in Vienna, Austria showing increased progression free survival compared to high dose octreotide LAR.
PRRT while available in many parts of the world has not yet been approved for use pending prospective randomized clinical trails (RCT). Having a positive RCT for PRRT will greatly expand access and availability to PRRT around the world. Click here to download the full release.
At the 2nd Theranostics World Congress there was progress towards the treatment of metastatic prostate cancer using a Theranostics approach. At the 3rd Theranostics World Congress that progress continued from the bench and to the bedside.
This video is an overview of the treatment and management of metastatic prostate cancer using a Theranostic Approach.